Introduction

Medial-compartment knee osteoarthritis (OA) is a common and often painful condition that primarily affects the inner part of the knee joint. This area is especially prone to damage because it carries a large share of the body's weight, especially in people with varus alignment—a bow-legged stance—that increases stress on the inner cartilage. Many patients find that general osteoarthritis treatments fail to fully relieve their symptoms, making targeted therapies essential for effective relief. One such promising treatment is Arthrosamid , a specially designed injection that offers cushioning directly where it’s needed most. This article explores how Arthrosamid can help people with persistent inner- knee pain caused by medial-compartment OA. We also highlight the expert care provided by Professor Paul Lee and the London Cartilage Clinic , who combine advanced knowledge and a patient-focused approach to deliver the best possible outcomes.

Understanding Medial-Compartment Knee Osteoarthritis

Medial-compartment knee OA occurs when the cartilage lining the inner side of the knee gradually wears away. To understand why this happens, it helps to know about varus load—a term that describes when the lower leg angles inward beneath the thigh, putting extra pressure on the inside part of the knee during everyday activities like walking and standing. This added load speeds up cartilage breakdown , leading to painful bone-on-bone contact and stiffness. People with this condition often notice they can’t walk as far, have trouble standing comfortably for long periods, and suffer from persistent joint stiffness that affects daily life. Because the damage mainly affects the medial compartment, treatments that specifically target this area tend to be more effective than general knee therapies . A focused approach is key to slowing disease progression and improving mobility. There is also an important aspect that is sometimes overlooked: joint instability. Research shows that “individuals with medial knee OA try to stabilise their knee by tightening the muscles on the inside of the joint” (Lewek et al., 2005). While this muscle action helps reduce the feeling of instability, it can inadvertently increase pressure on the joint, potentially speeding up damage if left unaddressed.

How Arthrosamid Works: Providing Cushioning for the Inner Knee

Arthrosamid is a synthetic gel made from polyacrylamide hydrogel , injected directly into the knee joint to act as an extra cushion. This material has properties similar to natural cartilage, meaning it absorbs shock and reduces the painful contact between bones that occurs in osteoarthritis . For medial-compartment OA, Arthrosamid is carefully injected into the part of the knee that bears the brunt of the pressure due to varus alignment. By cushioning this vulnerable area, the treatment reduces pain and supports improved knee function, helping patients walk further and stand more comfortably. A recent study found that “PAAG [ polyacrylamide hydrogel ] provided improvement in knee OA symptoms over 24 months, especially in older patients without diabetes and those with less severe disease” (Gao et al., 2025). These findings suggest that Arthrosamid can be particularly beneficial for certain groups of patients, enhancing its role as a targeted therapy.

The Patient Journey: The Importance of Expert Care and Support

The effectiveness of Arthrosamid depends a great deal on expert evaluation and ongoing clinical support. At the London Cartilage Clinic, Professor Paul Lee and his team conduct thorough assessments using detailed scans and physical examinations to determine which patients will benefit most from this treatment—usually those with confirmed damage to the medial compartment. This careful selection ensures the gel is exactly where it is needed, maximising symptom relief and improving function. Beyond technical skill, the clinic prides itself on creating a supportive environment where patients feel informed and confident about their treatment journey. Clear communication about realistic outcomes, attentive monitoring before and after injection, and personalised rehabilitation plans are all part of this comprehensive approach. It is worth noting that, as emphasised in recent research, “further studies are needed to confirm long-term benefits and to improve patient selection” (Gao et al., 2025). This highlights the ongoing role of expert clinical judgement and follow-up care in achieving the best outcomes.

What Patients and Clinicians Should Consider

If you are considering Arthrosamid for medial-compartment knee OA, it’s important to understand what the treatment involves and whether it’s suitable for you. This injection is most beneficial for those with confirmed OA in the inner knee who have not yet reached a stage where surgery, such as knee replacement, is necessary. The procedure is minimally invasive and generally well tolerated. Pain relief can last for two years or more, but individual results vary depending on age, disease severity, overall health and other personal factors. A thorough consultation with an orthopaedic specialist is essential to establish suitability and set realistic expectations. Studies show that “being older, having less severe OA, not having diabetes, and having both knees affected rather than just one increase the chances of meaningful improvement” (Gao et al., 2025). This information helps guide both patients and doctors in making informed decisions about treatment options. While Arthrosamid can ease symptoms and improve function, it does not restore damaged cartilage and does not replace the need for surgery in all cases. Professor Paul Lee’s extensive experience reminds us that personalised care plans which combine innovative treatments with comprehensive support offer the best prospects for long-term quality of life.

Conclusion

Medial-compartment knee osteoarthritis is a challenging condition that demands targeted treatment, given the high levels of stress on the inner knee. Arthrosamid presents an effective option by providing cushioning where it is needed most, reducing pain and aiding function. With the expert guidance of the London Cartilage Clinic and Professor Paul Lee, patients gain access to tailored assessment, precision treatment, and careful follow-up care. This combination ensures well-informed decisions and realistic expectations for recovery. For personalised medical advice, always consult a qualified healthcare professional.

References

Gao, H. C. K., Akhtar, M., Creedon, C., Nar, Ö. O., Verma, T., & Lee, P. Y. F. (2025). Polyacrylamide hydrogel injections in knee osteoarthritis: A PROMs-based 24 month cohort study. Journal of Clinical Orthopaedics and Trauma. https://doi.org/10.1016/j.jcot.2025.103136 Lewek, M. D., Ramsey, D. K., Snyder‐Mackler, L., & Rudolph, K. S. (2005). Knee stabilization in patients with medial compartment knee osteoarthritis. Arthritis & Rheumatism, 52(9), 2845–2853. https://doi.org/10.1002/art.21237